No, a Pill Did Not Almost Double Survival for Pancreatic Cancer Patients — Here's What the Trial Actually Showed
“A clinical trial shows a pill almost doubled survival for pancreatic cancer patients”
The argument in brief
Headlines claimed a pill nearly doubled survival for pancreatic cancer patients, likely referring to the POLO trial of olaparib. That trial did show tumors took roughly twice as long to grow in treated patients — but overall survival, meaning how long patients actually lived, was virtually identical between the pill and placebo groups (19.0 vs 19.2 months). The claim confuses two very different measures.
Data: NEJM POLO Trial, Golan et al. 2019
Why it spread
Pancreatic cancer is widely understood as a near-certain death sentence, so even a partial result feels like a lifeline. People share these stories out of genuine hope for themselves or loved ones, and media outlets use superlative language because it drives clicks. Almost nobody outside oncology knows the difference between progression-free survival and overall survival, so the distinction never gets challenged.
A clinical trial result has been widely shared with the claim that a pill almost doubled survival for pancreatic cancer patients. That framing is misleading. The most likely source is the POLO trial, published in the New England Journal of Medicine in 2019, which tested olaparib — a targeted pill — in patients whose tumors carried a BRCA gene mutation. The trial did show a striking result, but not the one being claimed.
What olaparib actually doubled was progression-free survival — the time before the cancer visibly worsened. Patients on the pill went 7.4 months before their disease progressed, compared to 3.8 months on placebo. That is a real and meaningful finding. But it is not the same as living longer. When researchers looked at overall survival — how long patients actually lived — there was no significant difference at all. Median survival was 19.0 months on olaparib versus 19.2 months on placebo, according to the POLO trial data.
Full Fact has flagged this exact pattern repeatedly: cancer headlines routinely conflate progression-free survival with overall survival, and readers have no reason to know these are different things. Progression-free survival measures when scans show change; overall survival measures death. A drug can delay visible tumor growth without extending life, and that appears to be what happened here.
There is also a population problem. Olaparib only works in patients with BRCA mutations, which the National Cancer Institute estimates applies to just 5 to 7 percent of pancreatic cancer patients. Even if the drug had improved overall survival in that group, applying the result to all pancreatic cancer patients would be wrong. A 2023 Lancet review of the field confirmed that no therapy has come close to doubling overall survival for pancreatic cancer broadly, and Cancer Research UK data shows five-year survival still sits around 10 to 12 percent.
This kind of misinformation spreads because pancreatic cancer is one of the most feared diagnoses there is, with survival odds that have barely budged for decades. Any hint of a breakthrough travels fast and far. Headlines get written around the most dramatic number in a study — and 'nearly doubled' sounds extraordinary — without explaining that the number being doubled was not the one that matters most to patients.
Sources
- NEJM / POLO Trial (Golan et al., 2019)
The POLO trial showed olaparib (a PARP inhibitor pill) significantly improved progression-free survival in BRCA-mutated metastatic pancreatic cancer patients (7.4 months vs 3.8 months), but did NOT significantly improve overall survival (OS). Median OS was 19.0 months vs 19.2 months.
- ASCO 2022 – NAPOLI-3 Trial
NAPOLI-3 showed NALIRIFOX improved overall survival vs nab-paclitaxel/gemcitabine (11.1 vs 9.2 months) in metastatic pancreatic cancer — a meaningful but modest improvement, not a doubling of survival.
- Cancer Research UK – Pancreatic Cancer Survival Statistics
Pancreatic cancer 5-year survival remains around 10-12% in the UK, reflecting that no single pill has dramatically transformed overall survival outcomes for the broad population.
- Full Fact – Cancer Treatment Claims
Full Fact has repeatedly noted that headlines about cancer breakthroughs often conflate progression-free survival with overall survival, and results in specific genetic subgroups are frequently overgeneralized to all patients.
- NCI – Pancreatic Cancer Treatment (PDQ)
The NCI notes that while targeted therapies like olaparib are approved for BRCA-mutated pancreatic cancer, they apply to a small subset (~5-7%) of patients and have not been shown to nearly double overall survival across the patient population.
- The Lancet – Pancreatic Cancer Outcomes Review (2023)
A 2023 Lancet review confirmed that while incremental progress has been made in pancreatic cancer treatment, no therapy has come close to doubling overall survival for the general pancreatic cancer population.
Related debunks
- Partially FalsePartially False: Rice Farmers Do Have Higher Arsenic Levels — But Compliant Rice Isn't the Main Culprit
- Partially FalsePuppet Shows Can Help With Grief — But It's Not a Sure Thing
- UnverifiableYes, Hantavirus Pulmonary Syndrome Really Does Kill 30–40% of People It Infects — Here's What the Data Shows